Feb 27, 2023
Neal Koller is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected...
Feb 27, 2023
Neal Koller is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected...
Feb 13, 2023
Dr. Joslyn Kirby is the President of the HS Foundation, which focuses on improving the lives of those who suffer from Hidradenitis Suppurativa, a skin condition caused by an overactive immune system. Generally people with this condition are misdiagnosed with skin infections and treated with ineffective antibiotics. As...
Feb 13, 2023
Dr. Joslyn Kirby is the President of the HS Foundation, which focuses on improving the lives of those who suffer from Hidradenitis Suppurativa, a skin condition caused by an overactive immune system. Generally people with this condition are misdiagnosed with skin infections and treated with ineffective antibiotics. As...
Oct 17, 2022
Paula Brown Stafford is the President, CEO, and Chairman of Novan, which is focused on the research, development, and commercialization of therapies for skin diseases using a novel chemical entity. The first target indication is molluscum contagiosum, a highly contagious viral skin infection caused by molluscipoxvirus...